C
Carol Knott
Researcher at Clinical Trial Service Unit
Publications - 5
Citations - 2208
Carol Knott is an academic researcher from Clinical Trial Service Unit. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 2, co-authored 4 publications receiving 1950 citations.
Papers
More filters
Journal ArticleDOI
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent,Martin J Landray,Christina Reith,Jonathan Emberson,David C. Wheeler,Charles R.V. Tomson,Christoph Wanner,Vera Krane,Alan Cass,Jonathan C. Craig,Bruce Neal,Lixin Jiang,Lai Seong Hooi,Adeera Levin,Lawrence Y. Agodoa,Mike Gaziano,Bertram L. Kasiske,Robert J. Walker,Ziad A. Massy,Bo Feldt-Rasmussen,Udom Krairittichai,Vuddidhej Ophascharoensuk,Bengt Fellström,Hallvard Holdaas,Vladimir Tesar,Andrzej Wiecek,Diederick E. Grobbee,Dick de Zeeuw,Carola Grönhagen-Riska,Tanaji Dasgupta,David Lewis,William G. Herrington,Marion Mafham,William Majoni,K Wallendszus,Richard H. Grimm,Terje R. Pedersen,Jonathan A. Tobert,Jane Armitage,Alex Baxter,Christopher Bray,Yiping Chen,Zhengming Chen,Michael Hill,Carol Knott,Sarah Parish,David Simpson,Peter Sleight,Alan Young,Rory Collins +49 more
TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
Journal ArticleDOI
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Christoph Wanner,Jennifer B. Green,Sibylle Hauske,Parminder K. Judge,Kaitlin Mayne,Sarah Yoon Ai Ng,Emily L. Sammons,Doreen Zhu,Natalie Staplin,David Preiss,William M. Stevens,K Wallendszus,R. Dayanandan,Carol Knott,Michael D. Hill,Jonathan Emberson,Susanne Brenner,Vladimir Cejka,Alfred K. Cheung,Zhihong Liu,Jing Li,Pei-Shiuan Chen Chen,Lai Seong Hooi,Takashi Kadowaki,Masaomi Nangaku,Adeera Levin,David Z.I. Cherney,Roberto Pontremoli,Aldo P. Maggioni,Shinya Goto,Aiko Tomita,Rajat Deo,Katherine R. Tuttle,Jens Eilbracht,Stefan Hantel,Mark Hopley,Martin J Landray,Colin Baigent,Richard Haynes,William G. Herrington,Martina Brueckmann,Francisco Javier Rossello Lozano,Peter Sandercock,Rudy Bilous,Charles L. Herzog,Paul K. Whelton,Janet Wittes,Derrick A Bennett,A. Burke,Richard Brown,Lucy Fletcher,Hannah Gosling,Emily Harding,Ryonfa Lee,Kevin Murphy,Yanru Qiao,Rachel Raff,Hui Yu,Marcela Fajardo-Moser,Andrea Lorimer,Donata Lucci,Anita Hepditch,A. Axler,Da-ang Hao,Cheng Beng Goh,Sarojini Sivanandam,Akiko Hashimoto,Wakako Negoro,Mori Tomoko +68 more
TL;DR: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD.
Journal ArticleDOI
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data
Parminder K. Judge,Richard Haynes,William G. Herrington,Ben Storey,Natalie Staplin,Angelyn Bethel,Louise Bowman,Nigel J. Brunskill,Paul Cockwell,R. Dayanandan,Michael Hill,Philip A. Kalra,John J.V. McMurray,Maarten W. Taal,David C. Wheeler,Martin J Landray,Colin Baigent,Alex Baxter,Carol Knott,Kevin T. Murphy,Keith Wheatley,Jonathan Emberson,Charles R.V. Tomson,Paul Roderick +23 more
TL;DR: UK HARP-III was a multicentre, double-blind, randomized controlled trial comparing the effects of sacubitril/valsartan and irbesartan on measured GFR after 12 months of therapy and important secondary outcomes include effects on albuminuria, change in eGFR over time and the safety and tolerability of sacubsubitrin/valsArtan in CKD.
Journal ArticleDOI
Improving efficiency of on-site monitoring in multicentre clinical trials by targeting visits
TL;DR: O Oversight of this trial was augmented by central statistical monitoring that identified high scoring sites as priority for further investigation and some low scoring sites identified by the country teams as potentially problematic were visited.
Journal ArticleDOI
How was it for you? - obtaining feedback from staff at study sites for the HPS2-thrive trial
TL;DR: A large number of respondents had been involved in both the recruitment and follow-up phases of HPS2-THRIVE, and the survey was easy to manage, with a relatively high response rate.